# Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease

> **NCT06607458** · PHASE2 · RECRUITING · sponsor: **Delcath Systems Inc.** · enrollment: 90 (estimated)

## Conditions studied

- Refractory Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Melphalan/HDS Followed by Consolidation Treatment with Trifluridine-tipiracil plus Bevacizumab
- **DRUG:** Trifluridine-tipiracil plus Bevacizumab Alone

## Key facts

- **NCT ID:** NCT06607458
- **Lead sponsor:** Delcath Systems Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-05
- **Primary completion:** 2026-12
- **Final completion:** 2027-10
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06607458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06607458, "Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06607458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*